LCTX
Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
$03
About Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Details
Daily high
$1.06
Daily low
$1.01
Price at open
--
52 Week High
$1.99
52 Week Low
$0.88
Market cap
260.5M
Dividend yield
-
Volume
4,714
Avg. volume
1.4M
P/E ratio
-5.59
Lineage Cell Therapeutics, Inc. Common Stock News
Details
Daily high
$1.06
Daily low
$1.01
Price at open
--
52 Week High
$1.99
52 Week Low
$0.88
Market cap
260.5M
Dividend yield
-
Volume
4,714
Avg. volume
1.4M
P/E ratio
-5.59